Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lapatinib - Novartis

Next Previous
Drug Profile

Lapatinib - Novartis

Alternative Names: 572016; Cipatinib; GSK-572016; GW 572016; GW-2016; GW-572016F; Lapatinib - GSK; Lapatinib ditosilate; Lapatinib ditosylate; Tykerb; Tyverb

Latest Information Update: 27 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Beth Israel Deaconess Medical Center; Eddingpharm; FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO; GlaxoSmithKline; GSK; National Taiwan University Hospital; Novartis; West German Study Group
  • Class Antineoplastics; Chlorobenzenes; Fluorobenzenes; Furans; Phenyl ethers; Quinazolines; Small molecules; Sulfones
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III Brain metastases
  • Phase II Colorectal cancer; Non-small cell lung cancer
  • No development reported Bladder cancer
  • Discontinued Gastric cancer; Head and neck cancer; Prostate cancer

Most Recent Events

  • 07 May 2024 GlaxoSmithKline and Novartis in collaboration with Jonsson Comprehensive Cancer Center completed a phase II trial in Glioblastoma (Newly diagnosed, Combination therapy) in USA (PO) (NCT01591577)
  • 04 Jan 2024 No development reported - Phase-II/III for Bladder cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom (PO)
  • 04 Jan 2024 No development reported - Phase-III clinical trials in Breast cancer (Neoadjuvant therapy, Combination therapy) in United Kingdom, Taiwan, Ukraine, Sweden, Spain, South Korea, Russia, Romania, Peru, Pakistan, Norway, Norway, Lithuania, India, Hungary, Hong Kong, Greece, Germany, France, Czech Republic, Italy (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top